Skip to main content

Live Webinar - Cardiac PET Imaging: What's new and how to start?

-

Thursday, October 22, 2020 - 6:53

<p><span><span><span><span><span><span><span>As our healthcare systems is constantly looking for more value medicine, the use of cardiac PET is rapidly expanding and becoming one of the pillar for cardiac imaging. Cardiac PET has been widely adopted because it provides : high diagnostic accuracy and it is safe, efficient and patient-centered.</span></span></span></span> </span></span></span></p> <p><span><span><span>IBA invites you to attend a free webinar presented by 2 leading figures of Nuclear Medicine: Dr. Terrence Ruddy and Dr Parthiban Arumugam.</span></span></span></p> <p><strong><span><span><span>When?</span></span></span></strong><span><span><span>&nbsp;November 12<sup>th</sup>, 3 - 4 pm CET (9-10 am EST)</span></span></span></p> <p><a href="https://us02web.zoom.us/webinar/register/9716033506184/WN_6ZB_TbMsSXedbk8SOHE4Vg"><span><span><span>Register here</span></span></span></a></p> <p><br /> <span><span><span><strong><span><span><span><span>What will you learn from the webinar ?</span></span></span></span></strong> </span></span></span></p> <ul> <li><strong><span><span><span><span><span><span><span><span><span>Cardiac PET Myocardial Perfusion Imaging in 2020 &nbsp;</span></span></span></span></span></span></span></span></span></strong></li> </ul> <p><span><span>&nbsp;</span></span><span><span><span><span><span><span><span>Dr Ruddy will start with the basic of PET Cardiac imaging versus other modalities and share the recent advances in the field including the last results of the ISCHEMIA trial and coming CMS AUC (Appropriate User criteria) and its potential impact in the field.<br /> <br /> Dr. Terrence Ruddy, FRCPC,FACC is the Director of Nuclear Cardiology at University of Ottawa Heart Institute and a Professor of Medicine and Radiology at the University of Ottawa.</span></span></span></span><br /> <br /> &nbsp; </span></span></span></p> <ul> <li><strong><span><span>&nbsp;</span></span><span><span><span><span><span><span><span><span><span>How to implement a Cardiac PET Program in your site?</span></span></span></span></span></span></span></span></span></strong></li> </ul> <p><span><span>&nbsp;</span></span><span><span><span><span><span><span><span>Dr Arumugam will share his expertise on how to plan and implement a PET Cardiac Imaging Program covering resources (cost of equipment, tracers and staffing requirements) and supporting guidelines from national and international societies and also additional information that perfusion PET can offer over and above SPECT for a more precise diagnosis.<br /> <br /> Dr Parthiban Arumugam is a Consultant Nuclear Medicine Physician at Manchester University NHS Foundation Trust in the United Kingdom Society.</span></span></span></span> </span></span></span></p> <p><a href="https://us02web.zoom.us/webinar/register/9716033506184/WN_6ZB_TbMsSXedbk8SOHE4Vg"><span><span><span>Register here</span></span></span></a></p>
Share

More news

-

IBA Launches versatile high-energy new Cyclotron

&nbsp; IBA leverages 35 years of experience and innovation in the new Cyclone® IKON with enhanced availability of theranostic radiopharmaceuticals and reduced radiopharmacy footprint &nbsp; Louvain-la-Neuve, Belgium, &nbsp;10 June 2021 -&nbsp; IBA (Ion Beam Applications S.A., EURONEXT), the world's leading provider of solutions for the diagnosis and treatment of cancer, today launches its new high energy and high-capacity cyclotron, the Cyclone® IKON, which offers the largest energy spectrum for PET and SPECT isotopes from 13 MeV to 30 MeV. The Cyclone® IKON was showcased during a virtual live event and the replay can be watched here. Currently, there are still a large number of patients for whom cancer treatment fails, despite major scientific advances. Nuclear medicine is emerging as a relevant modality to address this gap by extending overall survival and quality of life for cancer patients. Theranostics and targeted therapies allow the administration of radiation directly to the targeted cells, with minimal toxic side effects to surrounding healthy cells, unlike traditional modalities. The growing number of clinical trials (200+) and ongoing increase of new radiotherapeutic molecule developments support the great potential of radioligand therapy. &nbsp; “To enable this revolution, we must enhance the availability of novel isotopes and boost their production capacity. In its role, the cyclotron must be a reliable and sustainable production source of isotopes for the radiopharmaceutical industry and this is particularly the case for Germanium-68 (used for Germanium-68/Gallium-68 generators), Iodine-123 and other radioisotopes such as Copper-64, for which the demand has been consistently expanding year after year.” Bruno Scutnaire, Vice-President of IBA's RadioPharma Solutions Division commented. To address these new market needs, IBA has redesigned its previous model, Cyclone® 30 MeV, and created a next generation system, the Cyclone® IKON. It is more compact and versatile than ever and is capable of working over a large energy span (13 to 30MeV) with full current capacity to enable the large-scale and high-purity production of emerging PET, SPECT and “parent” isotopes.&nbsp; The first two units of the Cyclone® IKON have already been acquired by two leading companies in radiopharmaceuticals production: The Institute of Radioelements (IRE) in Belgium and Curium Pharma in St Louis, USA. Commissioning is scheduled for 2023. Renaud Dehareng, CEO of Curium Pharma said: “IBA has been a trusted partner of Curium for a long time. We selected IBA for its globally recognized expertise and due to the outstanding capabilities and reliability of the Cyclotron.” We selected IBA because of the reliability of its equipment. It has the most compact and efficient high energy cyclotron on the market." said Erich Kollegger, CEO of IRE. &nbsp; &nbsp;
See more